ZEJULA (niraparib) patient at yoga class

Not actual ZEJULA patients.

Why ZEJULA (niraparib)?

ZEJULA is a once-daily, oral maintenance treatment for women with newly diagnosed ovarian cancer and women with recurrent germline BRCA-mutated (gBRCAm) ovarian cancer, after the cancer has completely or partially responded to the most recent chemotherapy.

Take ZEJULA at home, or wherever you are.


That leaves more of your day to focus on what matters to you.


You don’t have to plan your schedule around ZEJULA. While it should be taken at approximately the same time each day, you can choose a time that’s convenient for you. ZEJULA can be taken with or without food, which means that you’re not tied to meal schedules. If you miss a dose, take the next one at your regularly scheduled time.

Do not take an extra dose to make up for a missed dose. If you vomit after taking a dose of ZEJULA, do not take an extra dose. Take your next dose at your scheduled time.

Treatment with ZEJULA requires routine monitoring. Your healthcare provider will do blood tests to check your blood cell counts before treatment with ZEJULA, weekly for the first month of treatment with ZEJULA, monthly for the next 11 months, then as needed during treatment with ZEJULA.

Your healthcare provider will check your blood pressure and heart rate at least weekly for the first two months, then monthly for the first year, and as needed thereafter during your treatment with ZEJULA.

Get more details on ZEJULA dosing plus information on how your doctor will monitor treatment.


Women smiling after yoga




ZEJULA may offer more time without your cancer recurring*


ZEJULA is used as a first-line maintenance treatment for women with and without a positive test for BRCA or HRD.†‡ In the recurrent setting, ZEJULA is used as a maintenance treatment for women having a germline BRCA mutation.



*In a first-line maintenance clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. In a recurrent maintenance clinical trial, ZEJULA delayed disease progression in patients with an inherited BRCA mutation for a median of 21 months vs 6 months with placebo. Results may vary. Median is the middle number in a set of data, also called the midpoint. The trials are ongoing to see if patients live longer overall with treatment.
HRD, or homologous recombination deficiency, occurs when cells have difficulty repairing themselves and appears in about 50% of women with ovarian cancer.
BRCA refers to a set of genes called BRCA1 and BRCA2. Mutations in BRCA genes increase a woman’s risk of developing ovarian cancer, but having a BRCA mutation does not mean a woman will develop ovarian cancer. BRCA mutations can be inherited, or passed from parents to their children.

Women enjoying coffee after yoga

ZEJULA is a PARP inhibitor


ZEJULA is a medication called a PARP inhibitor. A PARP inhibitor can target cells—including cancer cells—and prevent them from repairing damage to their DNA, which may keep cancer from coming back. ZEJULA can also impact other cells and tissues in the body.

Learn more about how ZEJULA works.



Is ZEJULA Right for Me?

ZEJULA is an ovarian cancer treatment option that may be used for women at different opportunities in their journey—and could be a next step in your path forward.


ZEJULA can be used as a:

First-Line Maintenance Treatment


For recently diagnosed advanced ovarian cancer that has responded (complete or partial response) to platinum-based chemotherapy

Recurrent gBRCAm Maintenance Treatment


For recurrent germline BRCA-mutated ovarian cancer that has responded (complete or partial response) to platinum-based chemotherapy

Frequently Asked

What is ZEJULA?



Who should consider ZEJULA?



How does ZEJULA work?